A detailed history of Marshall Wace, LLP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 976,893 shares of PTGX stock, worth $33.8 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
976,893
Previous 142,470 585.68%
Holding current value
$33.8 Million
Previous $3.27 Million 765.31%
% of portfolio
0.04%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$21.79 - $32.15 $18.2 Million - $26.8 Million
834,423 Added 585.68%
976,893 $28.3 Million
Q4 2023

Feb 14, 2024

BUY
$14.05 - $23.44 $1.7 Million - $2.83 Million
120,723 Added 555.12%
142,470 $3.27 Million
Q3 2023

Nov 14, 2023

SELL
$16.68 - $23.66 $2.38 Million - $3.38 Million
-142,753 Reduced 86.78%
21,747 $362,000
Q2 2023

Aug 14, 2023

SELL
$18.02 - $29.36 $21.7 Million - $35.3 Million
-1,201,580 Reduced 87.96%
164,500 $4.54 Million
Q1 2023

May 15, 2023

SELL
$10.78 - $25.38 $952,585 - $2.24 Million
-88,366 Reduced 6.08%
1,366,080 $31.4 Million
Q4 2022

Feb 14, 2023

BUY
$7.36 - $11.17 $4.71 Million - $7.15 Million
639,720 Added 78.52%
1,454,446 $15.9 Million
Q3 2022

Nov 14, 2022

BUY
$7.86 - $11.71 $2.76 Million - $4.11 Million
350,669 Added 75.57%
814,726 $6.87 Million
Q2 2022

Aug 15, 2022

BUY
$7.06 - $25.52 $3.28 Million - $11.8 Million
464,057 New
464,057 $3.67 Million
Q2 2021

Aug 13, 2021

SELL
$25.57 - $44.88 $2.22 Million - $3.89 Million
-86,691 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$19.02 - $31.15 $572,559 - $937,708
-30,103 Reduced 25.77%
86,691 $2.25 Million
Q4 2020

Feb 16, 2021

BUY
$18.49 - $25.13 $2.16 Million - $2.94 Million
116,794 New
116,794 $2.35 Million
Q3 2019

Nov 14, 2019

SELL
$9.41 - $16.56 $167,488 - $294,751
-17,799 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$8.98 - $12.96 $159,835 - $230,675
17,799 New
17,799 $216,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.7B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.